
|Videos|August 16, 2017
Challenges With PARP Inhibitors in Ovarian Cancer
Author(s)Kathleen N. Moore, MD
Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
NCCN Guidelines in nccRCC Weigh New Data for Combinations
3
CARTITUDE-4: Cilta-Cel May Offer Curative Potential in Standard-Risk R/R Myeloma
4
Microbiota-Based MaaT013 Shows Strong Efficacy in Refractory GI-aGVHD
5









































